SecBot SecBot
SECBOTREPLAY Home › Report › PRAX

PRAX · Investor Day pipeline update

Praxis Precision Medicines, Inc. · 8-K filed Nov 12, 2026 at 17:01 ET

At the news

NEUTRALIMPACT 4/10

8-K filed Nov 12, 2026 at 17:01 ET

Praxis Precision Medicines hosted an Investor Day on November 12, 2026, presenting commercial launch plans for two upcoming PDUFA dates in late 2026/early 2027 (relutrigine for SCN2A/SCN8A DEE and ulixacaltamide for essential tremor), updated clinical data including 86% seizure reduction at 18 months for relutrigine and positive FDA sensitivity analyses for ulixacaltamide, and an expanded pipeline across movement disorders, pain, epilepsy, and antisense oligonucleotide programs. The filing is a routine business update with no financial results; all revenue projections are analyst consensus or illustrative scenarios, not company guidance.

  • Relutrigine PDUFA date December 27, 2026 for SCN2A/SCN8A DEE; ulixacaltamide PDUFA date January 29, 2027 for essential tremor
  • Updated relutrigine open-label extension data showed 86% reduction in motor seizures from baseline at 18 months
  • Ulixacaltamide ESSENTIAL3 sensitivity analyses requested by FDA were consistent with primary result; 95-week long-term safety data showed durable ADL improvement
  • Company plans to initiate ulixacaltamide studies in Parkinson's disease, restless legs syndrome and autism spectrum disorder in 2027

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access